Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

Dow Jones received a payment from EQS/DGAP to publish this press release.

Advicenne / Key word(s): Miscellaneous 
Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris 
 
08-Apr-2019 / 17:45 CET/CEST 
 
*Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris* 
 
*Nîmes, France, April 8, 2019 (5:45 p.m. CET)* 
Advicenne is a specialty pharmaceutical company dedicated to patients 
suffering from rare and neglected diseases. The company has already started 
selling products but its flagship drug candidate, ADV7103, is currently 
pending European marketing authorization for distal renal tubular acidosis 
(dRTA), a condition characterized by an imbalance in the pH of the blood. At 
Advicenne, we are committed to developing and commercializing medications 
that are adapted to both children and adults - because pathbreaking 
treatments for rare diseases should be available to patients of all ages. 
 
Listed since end 2017 on Euronext Paris, Advicenne has a unique position on 
the stock market: 
 
  · One recent market approval in Europe for its treatment of moderate 
  sedation (ADV6209), out-licensed to Primex Pharmaceuticals and under 
  commercial launch (trade name Ozalin(R)) with a royalties & milestones 
  agreement of several tens of millions of Euros. 
 
  · A centralized market authorization application (MAA) procedure underway 
  to commercialize its lead asset, ADV7103, in Europe as soon as H2 2020, in 
  distal renal tubular acidosis (dRTA - an orphan renal disease) 
 
  · A phase III clinical trial ongoing with the same product, ADV7103, in 
  the same indication, dRTA, in USA & Canada (commercial launch expected in 
  2021) 
 
  · A phase III clinical trial ongoing with the same product but in another 
  orphan indication (cystinuria) in Europe 
 
  · 2 in-licensed products already generating revenue on the French market, 
  promoted by the Company's own salesforce 
 
These achievements make Advicenne one of the most advanced companies in the 
biotech sector, and allow it to pursue confidently its growth trajectory. 
 
*Contacts:* 
 
*Advicenne*                    *Press Relations* 
Luc-André Granier, Paul        Alize RP 
Michalet,                      Caroline Carmagnol & Tatiana 
Julie Rachline                 Vieira 
E-mail:                        E-mail: [e-mail] 
[e-mail]        [phone] 
[phone] 
*Financial Communications*     *US Investor Relations* 
NewCap                         Rx Communications Group, LLC 
Emmanuel Huynh & Alexia Faure  Paula Schwartz 
E-mail: [e-mail]    Email: [e-mail] 
[phone]           +001 917-322-2216 
 
*Forward-Looking Statements* 
This press release contains certain forward-looking statements relating to 
the business of Advicenne, which shall not be considered per se as 
historical facts. Such statements include estimates for future performance 
and estimates regarding anticipated operating losses, future revenues, 
capital requirements and needs for additional financing. In some cases, 
forward-looking statements can be identified by words such as "could," 
"should," "may," "expects," "anticipates," "believes," "intends," 
"estimates," "aims," "targets" or similar words. Although the management of 
Advicenne believes that these forward-looking statements are reasonably 
made, they are based largely on the current expectations of Advicenne as of 
the date of this press release and are subject to a number of known and 
unknown risks and uncertainties and other factors that may cause actual 
results, performance or achievements to be materially different from any 
future results, performance or achievements expressed or implied by these 
forward-looking statements. In particular, the expectations of Advicenne 
could be affected by, among other things, uncertainties involved in the 
placing on the market and commercialization of Advicenne products or any 
other risks and uncertainties developed or identified in any public 
documents filed by Advicenne with the French Financial Markets Authority 
(_Autorité des marchés financiers_ (AMF)), including those listed in Chapter 
4, "Risk Factors," of its reference document, filed with the latter on 
December 3, 2018, under number R.18-073. Notwithstanding the compliance with 
article 223-1 of the General Regulation of the AMF (the information 
disclosed must be "accurate, precise and fairly presented"), Advicenne 
disclaims any intention or obligation to publicly update or revise any 
forward-looking statements, whether as a result of new information, future 
events or otherwise. 
 
Dissemination of a Financial Wire News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
796581 08-Apr-2019 CET/CEST 
 
 

(END) Dow Jones Newswires

April 08, 2019 11:45 ET (15:45 GMT)